Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hassle-free stroke prevention offered by new drug, Stanford researcher says

21.11.2003


People who take a commonly prescribed yet problematic drug called Coumadin to prevent stroke or blood clots may soon have a hassle-free alternative, according to research at Stanford University School of Medicine. Results from a 7,329-person international study have found that a new drug called ximelegatran prevents strokes as effectively as Coumadin without the side effects or inconvenience.



"We think this will result in a huge shift in anti-coagulation therapy," said Gregory Albers, MD, professor of neurology and neurological sciences and director of the Stanford Stroke Center. Albers was a member of the steering committee that designed and directed the trial. Results from the 3,407-person international phase of the study will be published in the Nov. 22 issue of The Lancet. Albers and his colleagues presented results from the 3,922-person North American study at the American Heart Association meeting Nov. 11 in Orlando.

Coumadin effectively thins the blood and prevents strokes in people with a type of erratic heartbeat called atrial fibrillation. The problem is that the drug has a very narrow effective dose range – too little and it doesn’t work, too much and a person bleeds excessively. The drug also interacts with other medications and with food. Because of these complications, people on Coumadin must have their blood checked and dose adjusted regularly to make sure they are protected from stroke.


"Coumadin is very effective, but more than half of the people who should be receiving it don’t take the medication because of the inconvenience," Albers said.

In contrast, ximelegatran is just as effective as Coumadin but doesn’t require blood tests for dose adjustment and doesn’t interact with medications or food. "It’s essentially one-dose-fits-all," Albers said.

Called the Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation, or SPORTIF, the studies comparing ximelegatran to Coumadin took place in 25 countries. They included 7,329 patients who were treated with one of the two drugs for an average of nearly two years. These were the largest trials ever conducted on people with atrial fibrillation, Albers said.

During the trials, people in the two groups had similar rates of stroke or death, though those taking ximelegatran had fewer major bleeding incidents. Albers said the most important difference was that patients on Coumadin required constant dose adjustment while those on ximelegatran took the same dose throughout the trial.

Albers said that about 6 percent of people on ximelegatran had elevated levels of liver enzymes in the period between two to six months of treatment. This side effect usually disappeared without any consequences, but he said people on ximelegatran will need to have their liver function monitored during the first few months of therapy.

Albers said he expects ximelegatran to be approved by the U.S. Food and Drug Administration within the next year. It will be sold by the pharmaceutical company AstraZeneca under the brand name Exanta. Albers served as a consultant for AstraZeneca during the trial.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions – Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>